OnKure Therapeutics, Inc. Class A OKUR 深 滬
已收盤 05-08 16:00:00 美东时间
3.91
-0.050
-1.26%
華盛通- 最 高3.97
- 今 開3.92
- 成交量 8.96万股
- 最 低 3.85
- 昨 收 3.96
- 總市值 15.79万
- 52周最高 5.38
- 市盈率 靜 --
- 換手率 0.22%
- 52周最低 1.90
- 委 比 29.86%
- 總股本 4.04万
- 歷史最高 19.9992
- 量 比 0.66
- 振 幅 3.03%
- 歷史最低 1.70
- 每 手 1
- 風險率 0.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OnKure Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.
OnKure Therapeutics shares are trading lower after the company reported worse-t...
05-06 23:23
OnKure Therapeutics Q1 EPS $(1.11) Misses $(0.64) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.64) by 73.44 percent. This is a 6.72 percent increase over losses of $(1.19) per share
05-06 04:39
OnKure Therapeutics Enters Into Securities Purchase Agreement For Private Placement Raising Gross Proceeds Of ~$150M
-- Financing led by Access Biotechnology with participation from new and existing investors-- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies –
03-27 20:12
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Micron To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts updated ratings for MU, EPAM, WLTH, OKUR, BLDR, DMRC, JBIO, CRCL. See changes and ratings on analyst ratings page.
03-16 20:12
'[HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $27
HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $34 to $27.
03-16 19:27
OnKure Therapeutics Q4 EPS $(0.99) Misses $(0.75) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.75) by 32 percent. This is a 27.74 percent increase over losses of $(1.37) per share
03-13 04:16
HC Wainwright & Co. Reiterates Buy on OnKure Therapeutics, Maintains $34 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Buy and maintains $34 price target.
2025-08-26 22:34
OnKure Therapeutics Q2 EPS $(1.14) Beats $(1.26) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.26) by 9.88 percent. This is a 97.46 percent increase over losses of $(44.82) per share
2025-08-13 04:22
OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
OnKure Therapeutics reported Q2 2025 financial results and provided updates on its lead asset, OKI-219, a PI3Kα inhibitor. The company has completed enrollment in the monotherapy and fulvestrant combination arms of the PIKture-01 trial and initiated two new triplet arms for HR+ and HER2+ metastatic breast cancer. Data from the monotherapy and fulvestrant combination arms is expected in Q4 2025. OnKure also advanced its pan-mutant selective PI3Kα ...
2025-08-12 20:05
